<DOC>
	<DOCNO>NCT00561093</DOCNO>
	<brief_summary>Study efficiency safety oral nutritional supplement anti-inflammatory antioxidative property combine appetite stimulant anti-inflammatory property ( pentoxiphylline ) treatment malnutrition-inflammation-cachexia syndrome maintenance hemodialysis patient</brief_summary>
	<brief_title>Anit-Inflammatory Anti-Oxidative Nutrition Dialysis Patients</brief_title>
	<detailed_description>There 350,000 hemodialysis patient USA ; people end-stage kiney disease whose survival depend thrice weekly hemodialysis treatment dialysis clinic . Hemodialysis patient unacceptably high death rate , one every 4 5 patient die year . Almost half death believe heart disease . Because marker malnutrition inflammation low amount blood protein ( serum albumin &lt; 4.0 g/dL ) , rather traditional risk factor , among strong predictor early death malnutrition-inflammation appear closely related oxidative stress hemodialysis patient , would like examine hypotesis treat malnutrition-inflammation-oxidation mean nutritional support may improve outcome . Low serum albumin &lt; 4.0 g/dL observe almost half hemodialysis patient appear associated low appetite , wasting , inflammation , malfunction vessel , cardiovascular disease several fold increase mortality . We hypothesize malnutrition-inflammation significantly correct simple in-center oral nutritional support anti-inflammatory antioxidant property combine appetite stimulant anti-inflammatory property , lead improved clinical nutritional outcome measure hemodialysis patient . We propose National Institutes Health pilot/feasibility study dialysis patient 50-50 chance receive real treatment fake version ( placebo ) . This method call randomization , study type call `` randomized placebo-controlled clinical trial '' two arm , so-called 2x2 factorial design . Our propose study low-priced efficient operational system perform 8 10 DaVita dialysis clinic Los Angles area . During 2-year pilot/feasibility study , test whether propose nutritional anti-inflammatory treatment safe improve low serum albumin relevant outcomes 100 hemodialysis patient . Subjects adult hemodialysis patient serum albumin &lt; 4.0 g/dL . The nutritional support arm include combination 2 oral nutritional supplement ; i.e. , Nepro™ ( 8 oz ) , tailor malnourished hemodialysis patient ; condense anti-inflammatory module similar Oxepa™ ( 2 oz ) , design sick patient inflammation oxidative stress ; placebo . The appetite stimulating arm include medication know `` pentoxifylline '' ( also know Trental™ ) dose 400 mg daily placebo . If patient qualifies agree participate study , one month observation test , follow 16 week treatment , one additional month observation end . Both intervention administer thrice weekly routine hemodialysis 16 week . Nutritional , inflammatory oxidative measure , vessel wall ( endothelial ) function , quality life clinical measure obtain , , intervention . The safety tolerability treatment , feasibility study design , measurability outcome examine . We hope successful completion pilot/feasibility study campus lead design large-scale clinical trial national level improve survival dialysis patient use nutritional anti-inflammatory treatment . Figure 1 . Proposed pilot/feasibility study ( see Appendix 1 color version ) Group A ( n=25 ) Nepro/Oxepa ( 2 can ) + PTX ( 400 mg ) HD &amp; follow day Group B ( n=25 ) Nepro/Oxepa ( 2 CANS ) + placebo PTX HD &amp; follow day Group C ( n=25 ) Placebo 2 can + PTX ( 400 mg ) HD &amp; follow day Group D ( n=25 ) Placebo 2 can + placebo PTX HD &amp; follow day PTX : pentoxifylline HD : Hemodialysis</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Hypoalbuminemia</mesh_term>
	<mesh_term>Protein-Energy Malnutrition</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>At least 3 month maintenance hemodialysis , Last 3month average serum albumin &lt; 4.0 g/dl , Average monthly Kt/V &gt; 1.2 , Dialysis time 3 5 hour , Functioning AV graft fistula tunnel catheter switch 6 month , Standardized dialysis treatment per DaVita protocol . In case average 3month &lt; 4.0 g/dl last month serum albumin &lt; 4.0 g/dl ( worsen hypoalbuminemia ) patient qualify , 3month average nPNA &lt; 0.8 g/kg/day BMI &lt; 20 kg/m2 . Peritoneal dialysis Terminal illnesses life expectancy &lt; 6 month Maintenance hemodialysis le 5 month Concurrent appetite stimulant Use IDPN past 23 month Inability follow comply instruction guideline Likelihood pregnancy intention become pregnant Acute waste condition active systemic disease Pulse chemo therapy Noncompliance dialysis treatment Dialysis catheter may switch soon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hypoalbuminemia</keyword>
	<keyword>Protein-energy malnutrition</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Chronic Kidney disease ( CKD ) stage 5</keyword>
	<keyword>maintenance hemodialysis</keyword>
</DOC>